CurrentUnitedHealthcarePolicy N/A

Step therapy for Veregen (sinecatechins)

Defines UnitedHealthcare's step therapy requirement that members must try lower-cost topical alternatives before coverage of Veregen (sinecatechins) for external genital and perianal warts in immunocompetent patients.

Policy Summary

PayerUnitedHealthcare

PolicyStep therapy for Veregen (sinecatechins)

Policy CodePolicy N/A

Change TypeRoutine review — no material changes

Effective DateNov 1, 2025

Next Review DateAug 1, 2025

Key ActionObtain prior authorization showing documented trial and failure, contraindication, or intolerance to imiquimod or podofilox before approving Veregen.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

11/1/2025effective date

1required prior therapy (step)

4moauthorization duration

3P&T approvals

Coverage Criteria

Initial Therapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy / Step Requirement

Step requirement prior to Veregen

Initial authorization criteria

Required prior agent: History of failure, contraindication, or intolerance to imiquimod OR podofilox

Documentation required

Step	Required prior therapy	Coverage requirement
1	Imiquimod (Aldara) OR Podofilox (Conylox)	Member must have history of failure, contraindication, or intolerance to one of the listed agents prior to coverage of Veregen

Provider Actions and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Veregen (sinecatechins). Approvals are contingent on documentation that the patient has a history of failure, contraindication, or intolerance to a preferred agent (see required step). Authorization, when approved, will be issued for up to 4 months. State mandates, federal requirements, and the member's benefit plan may affect coverage; other policies and utilization management programs may also apply.

Affected agents: Imiquimod (generic Aldara); Podofilox (generic Conylox)
Authorization duration: 4 months
Coverage may be granted via automated approval using prior claim/medication history, ICD-10 diagnosis codes, and/or claim logic
Supply limits may apply

Step Therapy

Step Therapy Required

Member must try and have documented failure, contraindication, or intolerance to imiquimod or podofilox prior to coverage of Veregen. Documentation supporting trial and reason for failure/intolerance should be included with the request.

Required prior agents: Imiquimod (generic Aldara) OR Podofilox (generic Conylox)
Approval criterion: history of failure, contraindication, or intolerance to one of the above agents

Denial Risk

Denial Risk — Step Therapy Not Met

Requests lacking documentation of a trial and failure, contraindication, or intolerance to imiquimod or podofilox may be denied.

Denial trigger: No documented history of failure, contraindication, or intolerance to imiquimod or podofilox

Note

Evidence Accepted for Automated Approval

UnitedHealthcare may use prior claims, medication history, diagnosis codes (ICD-10), and claim logic to authorize Veregen without additional documentation when those data demonstrate the required prior therapy failure/contraindication/intolerance. Automated approval processes and supply limits vary by program.

Permissible evidence for automated approval: previous claim/medication history, ICD-10 diagnosis codes, and/or claim logic
Note: Supply limits may apply

Step requirement	Action required
Try imiquimod or podofilox prior to Veregen	Documented failure, contraindication, or intolerance to one agent is required for approval

Definitions

inv-08: Veregen (sinecatechins) — definition and indication

DrugVeregen (sinecatechins)

Formulation / RouteTopical ointment (external application)

IndicationTreatment of external genital and perianal warts in immunocompetent patients.

Place in therapyUsed after trial and documented failure, contraindication, or intolerance to lower‑cost topical alternatives (imiquimod or podofilox) per step therapy program.

Coverage scopeCoverage limited to indicated use for immunocompetent patients with external genital or perianal warts.

Background

Veregen (sinecatechins) is a topical medication indicated for the treatment of external genital and perianal warts in immunocompetent patients. UnitedHealthcare’s step therapy program requires members to try lower-cost topical alternatives — specifically imiquimod or podofilox — prior to authorizing Veregen. The step is intended to encourage use of these alternatives before covering Veregen; documentation of trial, failure, contraindication, or intolerance to one of the alternatives is required for approval.